{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-302356","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.158758+00:00","generated_at":"2026-06-21T06:00:10.691090+00:00","sec_items":["1.01","2.02","2.03","7.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ImmunityBio raises ~$100M via equity and debt; affiliate converts $56.6M note into equity","bullets":["Registered direct offering: 9,090,909 shares + warrants at $5.50 per unit, gross $50M.","New $50M promissory note from Nant Capital (affiliated with Dr. Soon-Shiong) at Term SOFR + 8%, due Dec 2023.","NantWorks converts ~$56.6M existing principal and accrued interest into common at $5.67/share.","Pro forma cash and securities ~$160M after net proceeds of ~$96.4M from equity and debt.","If fully exercised, warrants could yield up to $60M additional gross proceeds over two years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-302356","json":"https://secwatch.observer/filing/0001193125-22-302356.json","markdown":"https://secwatch.observer/filing/0001193125-22-302356.md","text":"https://secwatch.observer/filing/0001193125-22-302356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:00:10.691090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad8c874bbe5a64bf6cae0ea2b1f0dc0cadc988b4","claim":"ImmunityBio, Inc. incurred loan of $50.0 million with Nant Capital, LLC at Term SOFR plus 8.0% per annum maturing December 31, 2023.","evidence_excerpt":"On December 12, 2022, the Company executed a $50.0 million promissory note with Nant Capital, LLC","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$50.0 million"},{"label":"Counterparty","value":"Nant Capital, LLC"},{"label":"Rate","value":"Term SOFR plus 8.0% per annum"},{"label":"Maturity","value":"December 31, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"46ecacd2280d9a95d79a980792f2ec1e13ee9c42","claim":"ImmunityBio, Inc. entered into the “SPA” with an institutional investor valued at $50.0 million (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, ImmunityBio, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with an institutional investor (the “Investor”) for the purchase and sale in a registered direct offering of 9,090,909 shares of the Company’s common stock and warrants to purchase an additional 9,090,909 shares at an exercise price of $6.60 per share for a purchase price of $5.50 per share and accompanying warrant, generating gross proceeds from the offering of approximately $50.0 million before deducting placement agent fees and other estimated offering expenses.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"$50.0 million"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"},{"claim_id":"acf22b67c04520f096c26fc5d8d7680464f20c28","claim":"ImmunityBio, Inc. entered into $50.0 million promissory note with Nant Capital, LLC valued at $50.0 million (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, the Company executed a $50.0 million promissory note with Nant Capital, LLC (“Nant Capital”), an entity affiliated with Dr. Patrick Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Nant Capital, LLC"},{"label":"Value","value":"$50.0 million"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"},{"claim_id":"e4abf9dcec395793e2e7e8574b0f688775b4045d","claim":"ImmunityBio, Inc. entered into the “PAA” with Piper Sandler & Co. valued at cash fee equal to 6.0% of the gross proceeds (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, the Company also entered into a placement agency agreement (the “PAA”) with Piper Sandler & Co. (the “Placement Agent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Piper Sandler & Co."},{"label":"Value","value":"cash fee equal to 6.0% of the gross proceeds"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}